comprehensive -WSS

comprehensive

author：explore 2025-10-08 16:06:31 - browse：63697

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： The cancer stories no one wants to hear

hotspot

WSS

ASCO: Palliative care found as helpful given virtually as in person

Cord blood banking comes at a high cost to babies

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Woman returns to dialysis after doctors remove transplanted pig kidney

At ASCO, AstraZeneca reports strong data for breast cancer drug

Personalized medicine goes far beyond genetics

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Study links childhood stress with decline in older age

Trump demands the U.S. pay no more for drugs than other countries … again

How to ethically and practically extend health care to all

Medicare proposal to cover medical devices draws a mixed reaction

A controversial new treatment promises to make little people taller

After affirmative action ruling, medical educators look to 'holistic review'

Chris Christie meets with Zelenskyy during Ukraine trip

Medical records are filled with copy

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

hotspot

When waiting feels immoral: Empathy in the emergency department

Physicians aren't 'burning out.' They're suffering from moral injury

'Null' research findings aren't empty of meaning. Let's publish them

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

It costs an awful lot of money to give away a kidney

How to ethically and practically extend health care to all

knowledge

explore

hotspot

knowledge